Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Download PDF
May 3, 2016
/
News
Share
the Post
Related
Posts
Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Read More
Story from Ayu Oktariani, Bandung, Indonesia
Factsheet on updated WHO guidelines for the screening, care and treatment of persons with hepatitis C infection from TREAT Asia/amfAR
Patent Situation of The Key Product For Treatment of Hepatitis C: SOFOSBUVIR – WHO working paper, updated 2015
Strategies to Secure Access to Generic HCV Medicines
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Generic daclatasvir (60 mg) availability and India market pricing as of 30 January 2016
